Search Results 1661-1670 of 20436 for hepatitis

1. A Study Of ATR-101 For The Treatment Of Cushing’s Syndrome - Mayo Clinic

   HIV, hepatitis B, or hepatitis C positivity at screening; Any malignancy within the previous 10 years, other than curatively resected basal or squamous cell ...

2. Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   ... Hepatitis B or Hepatitis C; Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed four (4) weeks prior to first dose ...

3. Medications for liver failure

   If liver failure is caused by another condition, such as hepatitis B or autoimmune hepatitis, specific antiviral or immune-based medicines may be prescribed.

4. A Study to Evaluate TAB006, as Monotherapy and in Combination with Toripalimab, in Patients with Previously Treated, Advanced Malignancies - Mayo Clinic

   ... hepatitis B or C virus infection, unless hepatitis has been curatively treated. Patients with a prior history or evidence of hepatitis B or C virus ...

5. A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo) - Mayo Clinic

   * Positive hepatitis B (HBV) and hepatitis C (HCV) test at screening * Evidence of latent or active tuberculosis (TB) * History of drug or alcohol abuse ...

6. Infliximab (intravenous route) - Mayo Clinic

   Hepatitis B, active or history of or; Histoplasmosis (fungus infection) ... This medicine may increase your or your child's risk of having a lupus-like syndrome or ...

7. Efficacy And Safety Of Maribavir In Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory Or Resistant To Treatment - Mayo Clinic

   Subjects with CMV hepatitis will not be excluded despite having >5 times ULN at screening. Have positive results for human immunodeficiency virus (HIV) ...

8. A Phase III, Randomised Study Of Adjuvant Dato-DXd In Combination With Rilvegostomig Or Rilvegostomig Monotherapy Versus Standard Of Care, Following Complete Tumour Resection, In Participants With Stage I Adenocarcinoma NSCLC Who Are CtDNA-positive Or Have High-risk Pathological Features - Mayo Clinic

   Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled 8. History of active primary ...

9. (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis - Mayo Clinic

   ... hepatitis B surface antigen or hepatitis C virus (HCV) antibody 6. History of clinically significant bleeding event within 30 days before the first dose of ...

10. Prerequisites and Requirements - M.D. Program - Mayo Clinic Alix School of Medicine

    Hepatitis B vaccine: Learners must submit proof of immunity by quantitative serology (defined as >10mIU/mL). Please be aware there are two types of lab ...